Idiopathic Pulmonary Fibrosis Pipeline Analysis 2018 - Focusing On Clinical Trials And Results, Drug Profiling, Patents, Collaborations, And Other Recent Developments
- Published : Mar 2020
- Report Code : KSI061611508
- Pages : 114
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
Idiopathic Pulmonary Fibrosis Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Idiopathic Pulmonary Fibrosis Pipeline Analysis report covers 57 drugs currently in different phases of development. Idiopathic Pulmonary Fibrosis is a disease characterised by scarring of pulmonary tissue and thus leading to reduced lung efficiency and difficult breathing. The scarring causes the lungs to become stiffer and lose their elasticity. Symptoms of the disease are breathlessness, persistent cough, clubbing and fatigue. Diagnoses is done by a chest x-ray, breathing tests and bronchoscopy. Treatment include pulmonary rehabilitation, oxygen therapy and medication to help with symptoms and scarring.
The report provides Idiopathic Pulmonary Fibrosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are AdAlta Limited, Asahi Kasei Pharma Corporation, Capstone Therapeutics Corp., Galectin Therapeutics, Kadmon Corporation, LLC, Prometic Life Sciences Inc., Reviva Pharmaceuticals Inc., Synairgen plc and OliX Pharmaceuticals, Inc. among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company Profiles
6.1. AdAlta Limited
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Aeolus Pharma
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Allinky Biopharma
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. AnaMar AB
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Apceth Biopharma
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Asahi Kasei Pharma Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. aTyr Pharma
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Avalyn Pharma
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. BerGenBio ASA
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Biogen
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Bioneer Corp
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Blade Therapeutics, Inc.
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Boehringer Ingelheim
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT Kadmon Corporation, LLC
6.14. BreStem Therapeutics
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Capstone Therapeutics Corp.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Celdara Medical
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Celgene
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Chiesi Farmaceutici
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Cynata
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. FibroGen, Inc.
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.21. FibroStatin
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.22. Galapagos NV
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.23. Galectin Therapeutics
6.23.1. Introduction
6.23.2. Financials
6.23.3. Products and Services
6.23.4. SWOT
6.24. Galecto Biotech
6.24.1. Introduction
6.24.2. Financials
6.24.3. Products and Services
6.24.4. SWOT
6.25. Genkyotex
6.25.1. Introduction
6.25.2. Financials
6.25.3. Products and Services
6.25.4. SWOT
6.26. Gilead Sciences
6.26.1. Introduction
6.26.2. Financials
6.26.3. Products and Services
6.26.4. SWOT
6.27. HEC Pharm
6.27.1. Introduction
6.27.2. Financials
6.27.3. Products and Services
6.27.4. SWOT
6.28. iBio Inc.
6.28.1. Introduction
6.28.2. Financials
6.28.3. Products and Services
6.28.4. SWOT
6.29. Inventiva Pharma
6.29.1. Introduction
6.29.2. Financials
6.29.3. Products and Services
6.29.4. SWOT
6.30. Kadmon Corporation, LLC
6.30.1. Introduction
6.30.2. Financials
6.30.3. Products and Services
6.30.4. SWOT
6.31. Lung Therapeutics
6.31.1. Introduction
6.31.2. Financials
6.31.3. Products and Services
6.31.4. SWOT
6.32. MediciNova, Inc.
6.32.1. Introduction
6.32.2. Financials
6.32.3. Products and Services
6.32.4. SWOT
6.33. Merck
6.33.1. Introduction
6.33.2. Financials
6.33.3. Products and Services
6.33.4. SWOT
6.34. Mission Therapeutics
6.34.1. Introduction
6.34.2. Financials
6.34.3. Products and Services
6.34.4. SWOT
6.35. NBHL Ltd
6.35.1. Introduction
6.35.2. Financials
6.35.3. Products and Services
6.35.4. SWOT
6.36. Nitto BioPharma, Inc.
6.36.1. Introduction
6.36.2. Financials
6.36.3. Products and Services
6.36.4. SWOT
6.37. Nuformix
6.37.1. Introduction
6.37.2. Financials
6.37.3. Products and Services
6.37.4. SWOT
6.38. OliX Pharmaceuticals, Inc.
6.38.1. Introduction
6.38.2. Financials
6.38.3. Products and Services
6.38.4. SWOT
6.39. Patara Pharma, Inc.
6.39.1. Introduction
6.39.2. Financials
6.39.3. Products and Services
6.39.4. SWOT
6.40. Pharmaxis
6.40.1. Introduction
6.40.2. Financials
6.40.3. Products and Services
6.40.4. SWOT
6.41. Pliant Therapeutics, Inc.
6.41.1. Introduction
6.41.2. Financials
6.41.3. Products and Services
6.41.4. SWOT
6.42. Promedior, Inc.
6.42.1. Introduction
6.42.2. Financials
6.42.3. Products and Services
6.42.4. SWOT
6.43. Prometic Life Sciences Inc.
6.43.1. Introduction
6.43.2. Financials
6.43.3. Products and Services
6.43.4. SWOT
6.44. Proterris
6.44.1. Introduction
6.44.2. Financials
6.44.3. Products and Services
6.44.4. SWOT
6.45. Pulmatrix, Inc.
6.45.1. Introduction
6.45.2. Financials
6.45.3. Products and Services
6.45.4. SWOT
6.46. Reata Pharmaceuticals, Inc.
6.46.1. Introduction
6.46.2. Financials
6.46.3. Products and Services
6.46.4. SWOT
6.47. Redx Pharma Plc
6.47.1. Introduction
6.47.2. Financials
6.47.3. Products and Services
6.47.4. SWOT
6.48. Respira Therapeutics, Inc.
6.48.1. Introduction
6.48.2. Financials
6.48.3. Products and Services
6.48.4. SWOT
6.49. Reviva Pharmaceuticals Inc.
6.49.1. Introduction
6.49.2. Financials
6.49.3. Products and Services
6.49.4. SWOT
6.50. Ribomic
6.50.1. Introduction
6.50.2. Financials
6.50.3. Products and Services
6.50.4. SWOT
6.51. SAJE Pharma
6.51.1. Introduction
6.51.2. Financials
6.51.3. Products and Services
6.51.4. SWOT
6.52. Samumed, LLC
6.52.1. Introduction
6.52.2. Financials
6.52.3. Products and Services
6.52.4. SWOT
6.53. Sanofi
6.53.1. Introduction
6.53.2. Financials
6.53.3. Products and Services
6.53.4. SWOT
6.54. Segue Therapeutics, LLC
6.54.1. Introduction
6.54.2. Financials
6.54.3. Products and Services
6.54.4. SWOT
6.55. Sorrento Therapeutics, Inc
6.55.1. Introduction
6.55.2. Financials
6.55.3. Products and Services
6.55.4. SWOT
6.56. Synairgen plc
6.56.1. Introduction
6.56.2. Financials
6.56.3. Products and Services
6.56.4. SWOT
6.57. Therabron
6.57.1. Introduction
6.57.2. Financials
6.57.3. Products and Services
6.57.4. SWOT
6.58. Unity Biotechnology
6.58.1. Introduction
6.58.2. Financials
6.58.3. Products and Services
6.58.4. SWOT
6.59. Vero Biotech
6.59.1. Introduction
6.59.2. Financials
6.59.3. Products and Services
6.59.4. SWOT
6.60. Vicore Pharma
6.60.1. Introduction
6.60.2. Financials
6.60.3. Products and Services
6.60.4. SWOT
6.61. X-Rx, Inc.
6.61.1. Introduction
6.61.2. Financials
6.61.3. Products and Services
6.61.4. SWOT
6.62. Yuhan
6.62.1. Introduction
6.62.2. Financials
6.62.3. Products and Services
6.62.4. SWOT
6.63. ZAI Lab Limited
6.63.1. Introduction
6.63.2. Financials
6.63.3. Products and Services
6.63.4. SWOT
List of Tables
List of Figures
Aeolus Pharma
Allinky Biopharma
AnaMar AB
Apceth Biopharma
Asahi Kasei Pharma Corporation
aTyr Pharma
Avalyn Pharma
BerGenBio ASA
Biogen
Bioneer Corp
Blade Therapeutics, Inc.
Boehringer Ingelheim
BreStem Therapeutics
Capstone Therapeutics Corp.
Celdara Medical
Celgene
Chiesi Farmaceutici
Cynata
FibroGen, Inc.
FibroStatin
Galapagos NV
Galectin Therapeutics
Galecto Biotech
Genkyotex
Gilead Sciences
HEC Pharm
iBio Inc.
Inventiva Pharma
Kadmon Corporation, LLC
Lung Therapeutics
MediciNova, Inc.
Merck
Mission Therapeutics
NBHL Ltd
Nitto BioPharma, Inc.
Nuformix
OliX Pharmaceuticals, Inc.
Patara Pharma, Inc.
Pharmaxis
Pliant Therapeutics, Inc.
Promedior, Inc.
Prometic Life Sciences Inc.
Proterris
Pulmatrix, Inc.
Reata Pharmaceuticals, Inc.
Redx Pharma Plc
Respira Therapeutics, Inc.
Reviva Pharmaceuticals Inc.
Ribomic
SAJE Pharma
Samumed, LLC
Sanofi
Segue Therapeutics, LLC
Sorrento Therapeutics, Inc
Synairgen plc
Therabron
Unity Biotechnology
Vero Biotech
Vicore Pharma
X-Rx, Inc.
Yuhan
ZAI Lab Limited
Related Reports
| Report Name | Published Month | Get Sample PDF |
|---|---|---|
| Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market: 2023-2028 | May 2023 | |
| South America Nuclear Medicine Market Size: 2022 - 2027 | Mar 2021 | |
| North America Nuclear Medicine Market Size: 2022 - 2027 | Mar 2021 | |
| Middle East and Africa Nuclear Medicine Market Size: 2022 - 2027 | Mar 2021 | |
| European Nuclear Medicine Market Size: Report, 2022 - 2027 | Mar 2021 |